Selective elimination of pathogenic synovial fluid T-cells from Rheumatoid Arthritis and Juvenile Idiopathic Arthritis by targeted activation of Fas-apoptotic signaling

Immunology Letters

Volumn 138, Issue 2, 2011, Pages 161-168

  Bremer, Edwin ^a   Abdulahad, Wayel H ^a   de Bruyn, Marco ^a   Samplonius, Douwe F ^a   Kallenberg, Cees G M ^a   Armbrust, Wineke ^b   Brouwers, E ^a   Wajant, Harald ^c   Helfrich, Wijnand ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

^c UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Antibody fragment; Apoptosis; CD7; Fas; FasL; T cells

Indexed keywords

CD28 ANTIGEN; CD40 LIGAND; CD70 ANTIGEN; FAS ANTIGEN; FAS LIGAND; HYBRID PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

ADULT; AGED; APOPTOSIS; ARTICLE; BINDING AFFINITY; CHILD; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; JUVENILE RHEUMATOID ARTHRITIS; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; T CELL DEPLETION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD3; ANTIGENS, CD7; ANTIGENS, CD95; APOPTOSIS; ARTHRITIS, JUVENILE RHEUMATOID; CHILD; CHILD, PRESCHOOL; FAS LIGAND PROTEIN; FEMALE; HUMANS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DEPLETION; MALE; MIDDLE AGED; RANK LIGAND; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION; SYNOVIAL FLUID; T-LYMPHOCYTES; TH1-TH2 BALANCE;

EID: 79959556991     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2011.04.004     Document Type: Article

References (47)

1. Lubberts E., Koenders M.I., van den Berg W.B. The role of T-cell interleukin-17 in conducting destructive arthritis: lessons from animal models. Arthritis Res Ther 2005, 7:29-37.
2. Lubberts E. Th17 cytokines and arthritis. Semin Immunopathol 2010, 32:43-53.
3. Moreland L.W., Pratt P.W., Mayes M.D., et al. Double-blind, placebo-controlled multicenter trial using chimeric monoclonal anti-CD4 antibody, cM-T412, in rheumatoid arthritis patients receiving concomitant methotrexate. Arthritis Rheum 1995, 38:1581-1588.
4. Choy E.H., Chikanza I.C., Kingsley G.H., Corrigall V., Panayi G.S. Treatment of rheumatoid arthritis with single dose or weekly pulses of chimaeric anti-CD4 monoclonal antibody. Scand J Immunol 1992, 36:291-298.
5. Kirkham B.W., Thien F., Pelton B.K., Pitzalis C., Amlot P., Denman A.M., et al. Chimeric CD7 monoclonal antibody therapy in rheumatoid arthritis. J Rheumatol 1992, 19:1348-1352.
6. Schiff M., Keiserman M., Codding C., Songcharoen S., Berman A., Nayiager S., et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 2008, 67:1096-1103.
7. Chiang E., Kolumam G., Yu X., Francesco M., Lvelja S., Penq L., et al. Targeted depletion of lymphotoxin-[alpha]-expressing TH1 and TH17 cells inhibits autoimmune disease. Nat Med 2009, 15:766-773.
8. Dhein J., Walczak H., Baumler C., Debatin K.M., Krammer P.H. Autocrine T-cell suicide mediated by APO-1/(Fas/CD95). Nature 1995, 373:438-441.
9. Brunner T., Mogil R.J., LaFace D., Yoo N.J., Mahboubi A., Echeverri F., et al. Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature 1995, 373:441-444.
10. Salmon M., Scheel-Toellner D., Huissoon A.P., Pilling D., Shamsadeen N., Hyde H., et al. Inhibition of T cell apoptosis in the rheumatoid synovium. J Clin Invest 1997, 99:439-446.
11. Hoa T.T., Hasunuma T., Aono H., Masuko K., Kobata T., Yamamoto K., et al. Novel mechanisms of selective apoptosis in synovial T cells of patients with rheumatoid arthritis. J Rheumatol 1996, 23:1332-1337.
12. Matsuno H., Yudoh K., Nakazawa F., Sawai T., Uzuki M., Nishioka K., et al. Antirheumatic effects of humanized anti-Fas monoclonal antibody in human rheumatoid arthritis/SCID mouse chimera. J Rheumatol 2002, 29:1609-1614.
13. Modiano J.F., Sun J., Lang J., Vacano G., Patterson D., Chan D., et al. Fas ligand-dependent suppression of autoimmunity via recruitment and subsequent termination of activated T cells. Clin Immunol 2004, 112:54-65.
14. Peng S.L. Fas (CD95)-related apoptosis and rheumatoid arthritis. Rheumatology 2006, 45:26-30.
15. Tanaka M., Itai T., Adachi M., Nagata S. Downregulation of Fas ligand by shedding. Nat Med 1998, 4:31-36.
16. Schneider P., Holler N., Bodmer J., Hahne M., Frei K., Fontana A., et al. Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J Exp Med 1998, 187:1205-1213.
17. Suda T., Hashimoto H., Tanaka M., Ochi T., Nagata S. Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble fas ligand blocks the killing. J Exp Med 1997, 186:2045-2050.
18. Hashimoto H., Tanaka M., Suda T., Tomita T., Hayashida K., Takeuchi E., et al. Soluble Fas ligand in the joints of patients with rheumatoid arthritis and osteoarthritis. Arthritis Rheum 1998, 41:657-662.
19. Holler N., Tardivel A., Kovacsovics-Bankowski M., Hertig S., Gaide O., Martinon F., et al. Two adjacent trimeric Fas ligands are required for Fas signaling and formation of a death-inducing signaling complex. Mol Cell Biol 2003, 23:1428-1440.
20. Greaney P., Nahimana A., Lagopoulos L., Etter A.L., Aubry D., Attinger A., et al. A Fas agonist induces high levels of apoptosis in haematological malignancies. Leuk Res 2006, 30:415-426.
21. Samel D., Muller D., Gerspach J., Assohou-Luty C., Sass G., Tiegs G., et al. Generation of a FasL-based proapoptotic fusion protein devoid of systemic toxicity due to cell-surface antigen-restricted activation. J Biol Chem 2003, 278:32077-32082.
22. Bremer E., Cate B., Samplonius D., de Leij L., Helfrich W. CD7-restricted activation of Fas-mediated apoptosis: a novel therapeutic approach for acute T-cell leukemia. Blood 2006, 107:2863-2870.
23. Bremer E., ten Cate B., Samplonius D.F., Mueller N., Wajant H., Stel A.J., et al. Superior activity of fusion protein scFvRit:sFasL over cotreatment with rituximab and Fas agonists. Cancer Res 2008, 68:597-604.
24. Bremer E., Samplonius D., Peipp M., van Genne L., Kroesen B., Fey G., et al. Target cell restricted apoptosis induction of acute leukemic T cells by a recombinant tumor necrosis factor-related apoptosis-inducing ligand fusion protein with specificity for human CD7. Cancer Res 2005, 65:3380-3388.
25. Wyzgol A., Muller N., Fick A., Munkel S., Grigoleit G., Pfizenmaier K., et al. Trimer stabilization, oligomerization, and antibody-mediated cell surface immobilization improve the activity of soluble trimers of CD27L, CD40L, 41BBL, and glucocorticoid-induced TNF receptor ligand. J Immunol 2009, 183:1851-1861.
26. Abdulahad W.H., Kallenberg C.G., Limburg P.C., Stegeman C.A. Urinary CD4+ effector memory T cells reflect renal disease activity in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2009, 60:2830-2838.
27. Martinez-Lorenzo M.J., Anel A., Saez-Gutierrez B., Royo-Canas M., Bosque A., Alava M.A., et al. Rheumatoid synovial fluid T cells are sensitive to APO2L/TRAIL. Clin Immunol 2007, 122:28-40.
28. Martinez-Lostao L., Garcia-Alvarez F., Basanez G., Alegre-Aguaron E., Desportes P., Larrad L., et al. Liposome-bound APO2L/TRAIL is an effective treatment in a rheumatoid arthritis model. Arthritis Rheum 2010, 62:2272-2282.
29. Jin C., Chae S., Kim T., Yang H., Lee E., Song Y., et al. Effect of tumor necrosis factor-related apoptosis-inducing ligand on the reduction of joint inflammation in experimental rheumatoid arthritis. J. Pharm. Exp. Ther. 2010, 332:858-865.
30. Pace K., Hahn H., Pang M., Nguyen J., Baum L., Cutting Edge: CD7 delivers a pro-apoptotic signal during galectin-1-induced t cell Death. J Immunol 2000, 165:2331-2334.
31. Zhang X., Brunner T., Carter L., Dutton R.W., Rogers P., Bradley L., et al. Unequal death in t helper cell (Th)1 and Th2 effectors: Th1, but not Th2, effectors undergo rapid Fas/FasL-mediated apoptosis. J Exp Med 1997, 185:1837-1849.
32. Zhang X.R., Zhang L.Y., Devadas S., Li L., Keegan A.D., Shi Y.F. Reciprocal expression of TRAIL and CD95L in Th1 and Th2 cells: role of apoptosis in T helper subset differentiation. Cell Death Differ 2003, 10:203-210.
33. van Hamburg J.P., Mus A.M., de Bruijn M.J., de Vogel L., Boon L, Cornelissen F., et al. GATA-3 protects against severe joint inflammation and bone erosion and reduces differentiation of Th17 cells during experimental arthritis. Arthritis Rheum 2009, 60:750-759.
34. Zaiss M., Frey B., Hess A., Regulatory T Cells protect from local and systemic bone destruction in arthritis. J Immunol 2010, 184:7238-7246.
35. Oh S., Rankin A.L., Caton A.J. CD4+ CD25+ regulatory T cells in autoimmune arthritis. Immunol Rev 2010, 233:97-111.
36. Jiao Z., Wang W., Jia R., Li J., You H., Chen L., et al. Accumulation of FoxP3-expressing CD4+ CD25+ T cells with distinct chemokine receptors in synovial fluid of patients with active rheumatoid arthritis. Scand J Rheumatol 2007, 36:428-433.
37. Mottonen M., Heikkinen J., Mustonen L., Isomaki P., Luukkainen R., Lassila O. CD4+ CD25+ T cells with the phenotypic and functional characteristics of regulatory T cells are enriched in the synovial fluid of patients with rheumatoid arthritis. Clin Exp Immunol 2005, 140:360-367.
38. Cao D., van Vollenhoven R., Klareskog L., Trollmo C., Malmstrom V. CD25brightCD4+ regulatory T cells are enriched in inflamed joints of patients with chronic rheumatic disease. Arthritis Res Ther 2004, 6:R335-R346.
39. Ruprecht C., Gattorno M., Ferlito F., Gregorio A., Martini A., Lanzavecchia A., et al. Coexpression of CD25 and CD27 identifies FoxP3+ regulatory T cells in inflamed synovia. J Exp Med 2005, 201:1793-1803.
40. Abdulahad W.H., Boots A.M., Kallenberg C.G. FoxP3+ CD4+ T cells in systemic autoimmune diseases: the delicate balance between true regulatory T cells and effector Th-17 cells. Rheumatology (Oxford) 2010.
41. Nakae S., Nambu A., Sudo K., Iwakura Y. Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J Immunol 2003, 171:6173-6177.
42. Vermeire K., Heremans H., Vandeputte M., Huang S., Billiau A., Matthys P. Accelerated collagen-induced arthritis in IFN-gamma receptor-deficient mice. J Immunol 1997, 158:5507-5513.
43. Chabaud M., Lubberts E., Joosten L., van den Berg W., Miossec P. IL-17 derived from juxta-articular bone and synovium contributes to joint degradation in rheumatoid arthritis. Arthritis Res 2001, 3:168-177.
44. Plater-Zyberk C., Joosten L.A., Helsen M.M., Koenders M.I., Baeuerle P.A., van den Berg W.B. Combined blockade of granulocyte-macrophage colony stimulating factor and interleukin 17 pathways potently suppresses chronic destructive arthritis in a tumour necrosis factor alpha-independent mouse model. Ann Rheum Dis 2009, 68:721-728.
45. Zhang Y., Xu G., Zhang L., Roberts A., Shi Y. Th17 cells undergo Fas-mediated activation-induced cell death independent of IFN-{gamma}. J Immunol 2008, 181:190-196.
46. Song K., Chen Y., Göke R., Wilmen A., Seidel C., Göke A., et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an inhibitor of autoimmune inflammation and cell cycle progression. J Exp Med 2000, 191:1095-1104.
47. Schmidt D., Goronzy J.J., Weyand C.M. CD4+ CD7-CD28- T cells are expanded in rheumatoid arthritis and are characterized by autoreactivity. J Clin Invest 1996, 97:2027-2037.